

## HR 1537

### Advancing Hope Act of 2015

**Congress:** 114 (2015–2017, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Mar 23, 2015

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Mar 27, 2015)

**Official Text:** <https://www.congress.gov/bill/114th-congress/house-bill/1537>

## Sponsor

**Name:** Rep. Butterfield, G. K. [D-NC-1]

**Party:** Democratic • **State:** NC • **Chamber:** House

## Cosponsors (11 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Cohen, Steve [D-TN-9]	D · TN		Mar 23, 2015
Rep. Kelly, Mike [R-PA-3]	R · PA		Mar 23, 2015
Rep. McCaul, Michael T. [R-TX-10]	R · TX		Mar 23, 2015
Rep. Van Hollen, Chris [D-MD-8]	D · MD		Mar 23, 2015
Rep. Bilirakis, Gus M. [R-FL-12]	R · FL		Apr 28, 2015
Rep. Rangel, Charles B. [D-NY-13]	D · NY		Apr 28, 2015
Rep. Cárdenas, Tony [D-CA-29]	D · CA		May 15, 2015
Rep. Hastings, Alcee L. [D-FL-20]	D · FL		May 21, 2015
Rep. Dold, Robert J. [R-IL-10]	R · IL		Jun 10, 2015
Rep. Coffman, Mike [R-CO-6]	R · CO		Sep 25, 2015
Rep. Lance, Leonard [R-NJ-7]	R · NJ		Mar 7, 2016

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 27, 2015

## Subjects & Policy Tags

**Policy Area:**

Health

## Related Bills

Bill	Relationship	Last Action
114 S 1878	Related bill	Sep 30, 2016: Became Public Law No: 114-229.

## Advancing Hope Act of 2015

This bill amends the Federal Food, Drug, and Cosmetic Act to expand the priority review voucher program for rare pediatric diseases to include treatments for sickle cell disease and pediatric cancers.

The voucher program is extended by removing the provision terminating the program one year after the Food and Drug Administration's (FDA's) issuance of three rare pediatric disease vouchers.

A voucher may not be issued for a rare pediatric disease product if a voucher was issued for the product as a tropical disease product.

A tropical disease voucher may not be issued for a product that was approved, over two years before submitting an application to the FDA, for commercial marketing by a foreign government to treat a tropical disease.

## Actions Timeline

---

- **Mar 27, 2015:** Referred to the Subcommittee on Health.
- **Mar 23, 2015:** Introduced in House
- **Mar 23, 2015:** Referred to the House Committee on Energy and Commerce.